Preventative Human T-cell leukemia virus type 1 vaccineThe Need: Addressing the Global HTLV-1 Epidemic with a Novel Vaccine Human T cell leukemia virus type-1 (HTLV-1) is a significant global health concern, responsible for causing Adult T cell leukemia/lymphoma (ATLL) and human myelopathy/tropical spastic paraparesis (HAM/TSP). With over 10 million people potentially infected worldwide, and endemic regions spanning across several continents, the lack of effective vaccines or treatments poses a major challenge in these communities. Therefore, there is a pressing need to develop a novel vaccine that can prevent and potentially treat HTLV-1 associated diseases, protecting millions of individuals from life-threatening conditions. The Technology: A Breakthrough Vaccine for HTLV-1 Our proposed technology aims to develop a cutting-edge mRNA vaccine to combat HTLV-1-associated diseases. The vaccine will deliver an immunodominant viral protein encapsulated mRNA particle to initiate the adaptive immune response to control HTLV-1 infection. This approach enables accelerates vaccine development against a pathogen associated with a devastating and rapidly progressing cancer for which there is no widely available curative therapy. It also will inform the design of therapeutics targeting the envelope of other retroviruses, including human immunodeficiency virus type 1 (HIV-1). Commercial Applications:
Benefits/Advantages:
In conclusion, the development of a novel vaccine to prevent and treat HTLV-1-associated diseases is of paramount importance, given the widespread impact of this retrovirus on human health worldwide. Our technology's potential to stimulate robust immune responses, coupled with its multiple commercial applications and advantages, represents a significant step towards addressing the global HTLV-1 epidemic and improving the lives of millions of people affected by this debilitating condition. |
Tech IDT2022-038 CollegeCollege of Veterinary Medicine Licensing ManagerDahlman, Jason "Jay" InventorsCategories |